Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone augmentation of sertraline for obsessive-compulsive disorder
IRCT20180303038927N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of buspirone and sertraline in obsessive compulsive disorder (OCD) (2 arms), sponsored by Qazvin University of Medical Sciences. Primary endpoint: Yale-Brown Obsessive Compulsive Scale response. Started Jan 2019; status: completed.
02
Drugs
buspironesertraline
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20180303038927N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180303038927N1.